Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions

NCT00866216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-03-29

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the bioequivalence of Azithromycin Monohydrate 600 mg Tablets.

Conditions

Interventions

DRUG

Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals

DRUG

Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.

Sponsors & Collaborators

Principal Investigators

  • Alan S Marion · MDS Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2003-09-30
Completion
2003-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866216 on ClinicalTrials.gov